Key points are not available for this paper at this time.
Palivizumab prophylaxis administered to preterm infants 33 to 35 weeks' gestational age is associated with a significantly lower incidence of recurrent wheezing during the first 3 years of life.
Yoshihara et al. (Mon,) studied this question.